Minipress

(Prazosin)

ApprovedSmall molecule

Minipress is a small molecule that works as Adrenergic Receptor Alpha-1 Antagonist.[2] It is being used across 21 indications, with its most advanced program in Approved.[1]

Minipress is one of 314 small molecule programs targeting Neurogenic bladder. It is currently in Approved.

Indications

Total Trials

Active Trials

313

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Neurogenic BladderApproved

Methamphetamine DependenceApproved

Nicotine DependenceApproved

Benign Prostatic HyperplasiaActive, not recruiting

Urinary RetentionActive, not recruiting

Alzheimer DiseaseApproved

Alcohol AbuseApproved

Acute Stress ReactionApproved

Post-Traumatic Stress DisorderCompleted

Congestive Heart FailureActive, not recruiting

Neurogenic BladderApproved

Approved

Methamphetamine DependenceApproved

Approved

Nicotine DependenceApproved

Approved

Benign Prostatic HyperplasiaApproved

Active, not recruiting

Urinary RetentionPreclinical

Active, not recruiting

Alzheimer DiseaseApproved

Approved

Alcohol AbuseApproved

Approved

Acute Stress ReactionApproved

Approved

Post-Traumatic Stress DisorderApproved

Completed

Congestive Heart FailureApproved

Active, not recruiting

Showing 10 of 19 indications

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

Minipress

Pfizer

Approved

1 2

Biltricide

Bayer

Preclinical

3 3

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 4

Theo-Dur

Pfizer

Preclinical

1 5

Niclocide

Bayer

Preclinical

1 6

Alfenta

Jazz Pharmaceuticals

Preclinical

1 7

Foscavir

CClinigen, Inc.

Preclinical

6 8

Aurlumyn

BBTG International Inc.

Preclinical

1 9

Intuniv

PPromius Pharma, LLC

Preclinical

1 10

Clomid

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Post-Traumatic Stress Disorder

NCT03539614

Q2 2027

Phase 2Recruiting

Magnetic Resonance Imaging

NCT06629077

Phase 2Recruiting

Magnetic Resonance Imaging

NCT06629090

Q4 2032

ApprovedNot yet recruiting

Post-Traumatic Stress Disorder

NCT07862712

Clinical

Trials by Indication[1]

Post-Traumatic Stress Disorder5 trials

Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance

Terminated·SSeattle Institute for Biomedical and Clinical Research·N/A·NCT00202449·59 enrolled

Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder

Terminated·SSeattle Institute for Biomedical and Clinical Research·N/A·NCT00183430·20 enrolled

Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance

Completed·UUS Department of Veterans Affairs·Phase 4·NCT00108420

Show 2 more trials

From Hyperarousal to Hyperglycemia: Therapeutic Targeting of Noradrenergic Signaling in PTSD-Related Insulin Resistance

Not yet recruiting·VVA Office of Research and Development·Approved·NCT07862712·70 enrolled

Noradrenergic Biomarkers in PTSD: Precision Medicine & Mechanisms

Active, not recruiting·VVA Office of Research and Development·Phase 3·NCT03539614·87 enrolled

Alcohol Dependence3 trials

Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder

Completed·SSeattle Institute for Biomedical and Clinical Research·Phase 2·NCT01518972·30 enrolled

Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).

Completed·YYale University·Phase 3·NCT00744055·96 enrolled

Prazosin Alcohol Dependence IVR Study

Completed·UUniversity of Washington·Phase 4·NCT00167687·23 enrolled

Agitation3 trials

Alzheimer's in Long-Term Care--Treatment for Agitation

Completed·UUniversity of Washington·N/A·NCT00161473·24 enrolled

Prazosin for Agitation in Alzheimer's Disease

Completed·AAlzheimer's Disease Cooperative Study (ADCS)·Phase 2·NCT03710642·35 enrolled

Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease

Completed·SSeattle Institute for Biomedical and Clinical Research·N/A·NCT01126099·20 enrolled

Effectiveness2 trials

Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD

Completed·MMilton S. Hershey Medical Center·N/A·NCT02382848·9 enrolled

Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress

Completed·—·Phase 2·NCT02431936·50 enrolled

Alcohol Use Disorders2 trials

Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin

Completed·UUniversity of New Mexico·N/A·NCT01916941·36 enrolled

Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders

Completed·SSeattle Institute for Biomedical and Clinical Research·Phase 2·NCT02322047·31 enrolled

27 more indications

Magnetic Resonance Imaging2 trials

Cerebrovascular Responses to Acute Hypoperfusion

Recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT06629077·36 enrolled

Cerebrovascular Responses to Acute Hypoperfusion

Recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT06629090·36 enrolled

Alcoholism1 trial

Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment

Completed·UUniversity of Wisconsin, Madison·Phase 1/2·NCT02966340·70 enrolled

Attention1 trial

Effects of Prazosin on the Attention-Enhancing Effects of Nicotine

Withdrawn·UUniversity of Maryland, Baltimore·N/A·NCT03416569

Anxiety Disorder1 trial

Prazosin Use in Adults With Anxiety Disorders

Suspended·UUniversity of Manitoba·Phase 1·NCT03894345·20 enrolled

Treatment1 trial

Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans

Completed·UUniversity of Pittsburgh·N/A·NCT01637584·40 enrolled

Prophylaxis1 trial

Secondary Prophylaxis After Variceal Bleeding in Non-Responders

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 4·NCT00450164·50 enrolled

Voiding Dysfunction1 trial

Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction

Unknown status·TTabriz University·Phase 1/2·NCT00602186·80 enrolled

Suicidal Ideation1 trial

Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)

Completed·—·Phase 4·NCT02199652·20 enrolled

Craving1 trial

Prazosin for ETOH or Cocaine Craving

Terminated·UUS Department of Veterans Affairs·N/A·NCT00240227·8 enrolled

Post-Traumatic Stress Disorder, PTSD1 trial

Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD)

Completed·UUniversity of Pittsburgh·N/A·NCT00393874·50 enrolled

Cardiovascular1 trial

The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study

Withdrawn·UUniversity of Louisville·Phase 1·NCT03010995

Blood Pressure1 trial

A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

Terminated· Otsuka logo

Otsuka·Phase 1·NCT05189977·34 enrolled

Trauma1 trial

Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD

Completed·VVA Office of Research and Development·Phase 3·NCT00532493·304 enrolled

Smoking Cessation1 trial

Prazosin for Smoking Cessation

Terminated·CCentre for Addiction and Mental Health·Phase 2·NCT01642433·1 enrolled

Methamphetamine Abuse1 trial

Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin

Completed·UUniversity of Arkansas·Phase 2·NCT01178138·24 enrolled

Smokers1 trial

Varenicline + Prazosin for Heavy Drinking Smokers

Completed·YYale University·Phase 1·NCT02193256·5 enrolled

Women1 trial

Administration of Prazosin to Prevent PTSD in Adult Women After Sexual Assault

Withdrawn·UUniversity of Colorado, Denver·Phase 4·NCT03997864

Relapse1 trial

Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse

Completed·YYale University·Phase 1/2·NCT00585780·100 enrolled

Chronic Hepatitis1 trial

Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis

Unknown status·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00148837·112 enrolled

MPA1 trial

A Comparative Study of Using Scorpion Antivenom Versus Scorpion Antivenom and Prazosin

Unknown status·SSohag University·Phase 4·NCT06287905·80 enrolled

Stress1 trial

Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees

Completed·UUS Department of Veterans Affairs·N/A·NCT00261729·210 enrolled

Morbidity1 trial

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

Completed·UUniversity of Washington·N/A·NCT02655354·635 enrolled

Headache1 trial

Prazosin for Post-Concussive Headaches

Completed·SSeattle Institute for Biomedical and Clinical Research·Phase 4·NCT02965027·89 enrolled

PTSD1 trial

Feasibility Study: The Effect of Prazosin for Nighttime Symptoms of Civilian PTSD

Unknown status·RRainier Associates·N/A·NCT00174551·20 enrolled

COVID-191 trial

Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)

Terminated·JJohns Hopkins University·Phase 2·NCT04365257·5 enrolled

Alcohol Withdrawal1 trial

Prazosin Treatment for Alcohol Use Disorder With Alcohol Withdrawal Symptoms

Completed·YYale University·Phase 2·NCT04793685·152 enrolled

Unspecified1 trial

Alfuzosin for Medical Expulsion Therapy of Ureteral Stones

Unknown status·UUnited States Naval Medical Center, San Diego·Phase 3·NCT00713739·240 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

MINIPRESS

NDA NDA017442

Jan 29, 1992

MINIPRESS XL

NDA NDA019775

Sources

References

[1]
ClinicalTrials.gov — 43 trial records for Prazosin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prazosin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prazosin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA019775). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Adrenergic Receptor Alpha-1 Antagonist[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

Minipress

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2032

Trials by Indication[1]

Post-Traumatic Stress Disorder5 trials

Alcohol Dependence3 trials

Agitation3 trials

Effectiveness2 trials

Alcohol Use Disorders2 trials

Magnetic Resonance Imaging2 trials

Alcoholism1 trial

Attention1 trial

Anxiety Disorder1 trial

Treatment1 trial

Prophylaxis1 trial

Voiding Dysfunction1 trial

Suicidal Ideation1 trial

Craving1 trial

Post-Traumatic Stress Disorder, PTSD1 trial

Cardiovascular1 trial

Blood Pressure1 trial

Trauma1 trial

Smoking Cessation1 trial

Methamphetamine Abuse1 trial

Smokers1 trial

Women1 trial

Relapse1 trial

Chronic Hepatitis1 trial

MPA1 trial

Stress1 trial

Morbidity1 trial

Headache1 trial

PTSD1 trial

COVID-191 trial

Alcohol Withdrawal1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News